stonks4u
Sign up free
OLMA logo

OLMA Olema Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$10.63
+0.12 (+1.14%)

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen rece…

Market Cap: $928.50Mwww.olema.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 11Aug 11

Quote

Day Range
$10.29 – $10.75
52-Week Range
$5.34 – $36.26
Volume
$1.12M
Market Cap
$928.50M
50-Day Avg
$11.22
200-Day Avg
$17.57
Prev Close
$10.51
Open
$10.44

Valuation & Ratios

P/E Ratio
-13.37
EPS
$-1.87
P/B Ratio
4.55
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
9.95
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-33.9%
Return on Assets
-30.5%
FCF Yield
-6.7%
EV/EBITDA
-13.14

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-162.45M$-1.87
2024$0.00$-129.47M$-2.20
2023$0.00$-96.66M$-2.14
2022$0.00$-104.79M$-2.62
2021$0.00$-71.10M$-1.79

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $-0.59 per share

4of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$-0.61 vs $-0.55miss
  • Tue, May 12$-0.52 vs $-0.52beat
  • Mon, Mar 16$-0.50 vs $-0.51beat
  • Mon, Nov 10$-0.49 vs $-0.44miss
  • Mon, Aug 11$-0.51 vs $-0.43miss
  • Tue, May 13$-0.36 vs $-0.49beat

Estimates and results for OLMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

OLMAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsbenzinga.com·4d ago·Neutral

    Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027.

    View source ↗